These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 19696692)

  • 1. Nonmyeloablative allogeneic hematopoietic stem cell transplantation as immunotherapy for pancreatic cancer.
    Abe Y; Ito T; Baba E; Nagafuji K; Kawabe K; Choi I; Arita Y; Miyamoto T; Teshima T; Nakano S; Harada M
    Pancreas; 2009 Oct; 38(7):815-9. PubMed ID: 19696692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.
    Tykodi SS; Warren EH; Thompson JA; Riddell SR; Childs RW; Otterud BE; Leppert MF; Storb R; Sandmaier BM
    Clin Cancer Res; 2004 Dec; 10(23):7799-811. PubMed ID: 15585611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful outcome after nonmyeloablative allogeneic hematopoietic stem cell transplantation in patients with renal dysfunction.
    Kersting S; Verdonck LF
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1312-6. PubMed ID: 18940687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant.
    Feinstein LC; Sandmaier BM; Maloney DG; Maris MB; Gooley TA; Chauncey TR; Hegenbart U; McSweeney PA; Stuart MJ; Forman SJ; Agura EA; Pulsipher MA; Blume KG; Niederwieser DW; Storb RF
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):266-72. PubMed ID: 12720219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.
    Levine JE; Uberti JP; Ayash L; Reynolds C; Ferrara JL; Silver SM; Braun T; Yanik G; Hutchinson R; Ratanatharathorn V
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):189-97. PubMed ID: 12652470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.
    Schlenk RF; Hartmann F; Hensel M; Jung W; Weber-Nordt R; Gabler A; Haas R; Ho AD; Trümper L; Döhner H
    Leukemia; 2002 Apr; 16(4):581-6. PubMed ID: 11960336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies.
    Rodriguez R; Parker P; Nademanee A; Smith D; O'Donnell MR; Stein A; Snyder DS; Fung HC; Krishnan AY; Popplewell L; Cohen S; Somlo G; Angelopoulou M; Al-Kadhimi Z; Falk PM; Spielberger R; Kogut N; Sahebi F; Senitzer D; Slovak M; Schriber J; Forman SJ
    Bone Marrow Transplant; 2004 Jun; 33(11):1123-9. PubMed ID: 15064696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation.
    Loren AW; Luger SM; Stadtmauer EA; Tsai DE; Schuster S; Nasta SD; Goldstein SC; Perl A; Orloff G; Oliver JC; Green J; Emerson SG; Porter DL
    Bone Marrow Transplant; 2005 May; 35(9):921-6. PubMed ID: 15765118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect.
    Feinstein L; Sandmaier B; Maloney D; McSweeney PA; Maris M; Flowers C; Radich J; Little MT; Nash RA; Chauncey T; Woolfrey A; Georges G; Kiem HP; Zaucha JM; Blume KG; Shizuru J; Niederwieser D; Storb R
    Ann N Y Acad Sci; 2001 Jun; 938():328-37; discussion 337-9. PubMed ID: 11458521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for neo-generation of T cells by the thymus after non-myeloablative conditioning.
    Castermans E; Baron F; Willems E; Schaaf-Lafontaine N; Meuris N; Gothot A; Vanbellighen JF; Herens C; Seidel L; Geenen V; Cheynier R; Beguin Y
    Haematologica; 2008 Feb; 93(2):240-7. PubMed ID: 18223286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fludarabine-based conditioning chemotherapy for allogeneic hematopoietic stem cell transplantation in acquired severe aplastic anemia.
    Al-Zahrani H; Nassar A; Al-Mohareb F; Al-Sharif F; Mohamed S; Al-Anazi K; Patel M; Rasheed W; Saleh AJ; Bakr M; Ahmed S; Ibrahim K; Hussain F; Elkum N; Elhassan T; Nurgat Z; Chaudhri N; Aljurf M
    Biol Blood Marrow Transplant; 2011 May; 17(5):717-22. PubMed ID: 20736079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unrelated donor hematopoietic stem cell transplantation for patients with hematologic malignancies using a nonmyeloablative conditioning regimen of fludarabine, low-dose total body irradiation, and rabbit antithymocyte globulin.
    Rowley SD; Goldberg SL; Pecora AL; Hsu JS; Brecher BA; Butrin L; Kobbe K; McKiernan P; Preti R
    Biol Blood Marrow Transplant; 2004 Nov; 10(11):784-93. PubMed ID: 15505609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new minimally ablative stem cell transplantation procedure in high-risk patients not eligible for nonmyeloablative allogeneic bone marrow transplantation.
    Shapira MY; Or R; Resnick IB; Bitan M; Ackerstein A; Samuel S; Elad S; Zilberman I; Miron S; Slavin S
    Bone Marrow Transplant; 2003 Sep; 32(6):557-61. PubMed ID: 12953126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for congenital sideroblastic anemia.
    Medeiros BC; Kolhouse JF; Cagnoni PJ; Ryder J; Nieto Y; Rabinovitch R; Shpall EJ; Bearman SI; Jones RB; McSweeney PA
    Bone Marrow Transplant; 2003 Jun; 31(11):1053-5. PubMed ID: 12774059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
    Pedrazzoli P; Da Prada GA; Giorgiani G; Schiavo R; Zambelli A; Giraldi E; Landonio G; Locatelli F; Siena S; Della Cuna GR
    Cancer; 2002 May; 94(9):2409-15. PubMed ID: 12015766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of kidney function impairment after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. A single-center experience.
    Piñana JL; Valcárcel D; Martino R; Barba P; Moreno E; Sureda A; Vega M; Delgado J; Briones J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):21-9. PubMed ID: 19135939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Establishment of rhesus model for haploidentical hematopoietic stem cell transplantation with nonmyeloablative conditioning].
    Liu LH; Sun QY; Hu KX; Fan CB; Huang YJ; Bian L; Xiao XB; Yao B; Guo M; Yu CL; Ai HS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug; 13(4):677-82. PubMed ID: 16129059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.